To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC70209 | AS105 Featured |
AS105 (AS-105) is a highly potent, ATP-competitive CaMKII inhibitor, inhibits CaMKIIδ with IC50 of 8 nM, Ki of 3 nM.
AS105 is also effective against autophosphorylated CaMKII (in contrast to the commonly used allosteric CaMKII-inhibitor KN-93).
In isolated atrial cardiomyocytes from human donors and ventricular myocytes from CaMKIIδC-overexpressing mice with heart failure, AS105 effectively reduced diastolic SR Ca2+ leak by 38% to 65% as measured by Ca2+-sparks or tetracaine-sensitive shift in [Ca2+]i.
AS105 effectively reduced SR Ca2+-leak, thus improving SR Ca2+-accumulation and reducing cellular arrhythmogenic correlates, without negatively influencing excitation-contraction coupling.
More description
|
|
| DC65805 | BMS-986365 (CC-94676) Featured |
BMS-986365 (CC-94676) is a highly potent and selective AR degrader that induces rapid and deep degradation of both wildtype and mutant forms of the receptor residing in either the cytoplasmic or nuclear compartments of the cell. BMS-986365 (CC-94676) is about 100-fold more potent than enzalutamide (ENZ) at inhibiting androgen-stimulated transcription of AR target genes, and 10 to 120-fold more potent than ENZ at inhibiting AR-dependent proliferation of multiple prostate cancer cell lines in vitro.
More description
|
|
| DC70103 | MS.001 Featured |
MS.001 is a small molecule that inhibits both the chaperone binding and ubiquitin ligase activity of C-terminus of Hsc70 interacting protein (CHIP) at low micromolar concentrations (IC50=3.3 uM).
More description
|
|
| DC70343 | DCC-3116 Featured |
DCC-3116 (DCC3116) is a first-in-class, selective inhibitor of ULK1/2 kinases (IC50=4.7/35 nM) and autophagy.DCC-3116 is an oral ULK1/2 inhibitor targeting the autophagy pathway, a key mechanism of tumor survival and resistance to targeted therapy.
More description
|
|
| DC66089 | Benzamil Featured |
Benzamil (Benzylamiloride), an Amiloride analogue, is a Na+/Ca2+ exchanger (NCX) inhibitor (IC50~100 nM). Benzamil also is a non-selective Deg/epithelial sodium channels (ENaC) blocker, and can potentiate myogenic vasoconstriction. Benzamil inhibits TRPP3-mediated Ca2+-activated currents, with an IC50 of 1.1 μM.
More description
|
|
| DC37530 | Diloxanide furoate Featured |
Diloxanide furoate is an ambecide, an anti-protozoal drug used in the treatment of amoebozoa infections
More description
|
|
| DC66088 | Propoxycaine Hydrochloride Featured |
Propoxycaine hydrochloride inhibits voltage-gated sodium channels, and thereby inhibits the ionic flux required for the initiation and conduction of impulses. Propoxycaine hydrochloride application can lead to a loss of sensation.
More description
|
|
| DC66087 | 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxypyridin-2(1H)-one Featured |
|
|
| DC21624 | SBI-425 Featured |
SBI-425 (SBI425) is a potent, selective, orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor with IC50 of 16 nM, shows high selectivity over other alkaline phosphatases including IAP and PLAP.
More description
|
|
| DC66086 | 2(1H)-Pyridinone, 4-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]-5-fluoro- Featured |
|
|
| DC66085 | 4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-5-fluoropyridin-2(1H)-one Featured |
|
|
| DC66084 | NSC 13695 Featured |
|
|
| DC66083 | Indantadol Featured |
Indantadol is a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain.
More description
|
|
| DC66082 | Soretolide Featured |
Soretolide is an orally active benzamide derivative with anticonvulsant effects and a similar profile of activity to carbamazepine
More description
|
|
| DC66081 | Oxatomide-HCl Featured |
|
|
| DC40317 | Oxatomide Featured |
Oxatomide is a potent and orally active dual H1-histamine receptor and P2X7 receptor antagonist with antihistamine and anti-allergic activity. Oxatomide almost completely blocks the ATP-induced current in human P2X7 receptors (IC50 of 0.95 μM). Oxatomide inhibits ATP-induced Ca2+ influx with an IC50 value of 0.43 μM and also inhibits serotonin.
More description
|
|
| DC66080 | (E)-1-methyl-4-(4-(methyl(2-(stearoyloxy)ethyl)amino)styryl)pyridin-1-ium Featured |
|
|
| DC66079 | NMDAR/TRPM4-IN-2 Featured |
NMDAR/TRPM4-IN-2 (compound 8) is a potent NMDAR/TRPM4 interaction interface inhibitor. NMDAR/TRPM4-IN-2 shows neuroprotective activity. NMDAR/TRPM4-IN-2 prevents NMDA-induced cell death and mitochondrial dysfunction in hippocampal neurons, with an IC50 of 2.1 μM. NMDAR/TRPM4-IN-2 protects mice from MCAO-induced brain damage and NMDA-induced retinal ganglion cell loss.
More description
|
|
| DC66078 | WAY-299026 Featured |
|
|
| DC66077 | DpC Featured |
DpC is an anti-tumor agent. DpC inhibits cancer cell proliferation (IC50: 0.007-0.096 渭M). DpC synergizes with multiple anti-cancer therapeutics.
More description
|
|
| DC66076 | SNX7 Featured |
SNX7 is a Cyclin-Dependent Kinase Inhibitor (CDKI) pathway inhibitor. SNX7 can be used for research of senescence-related and other CDKI-related diseases.
More description
|
|
| DC66075 | WAY-608306 Featured |
|
|
| DC66074 | BTK ligand 1 Featured |
BTK ligand 1 (compound 1) is a ligand targeting Bruton’s tyrosine kinase (Btk). BTK ligand 1 can combine with E3 ligase ligand (Ligand for E3 Ligase) through PROTAC Linker to form PROTAC. PROTACs targeting Btk can be used in the study of chronic lymphocytic leukemia (CLL) and other BK cell malignancies.
More description
|
|
| DC66073 | WAY-639497 Featured |
altering the lifespan of a eukaryotic organism; antibacterial agent;
More description
|
|
| DC66072 | TC-F2 Featured |
TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders.
More description
|
|
| DC66071 | 4-Hydroxyretinoic acid Featured |
4-Hydroxyretinoic acid (4-HRA) is a naturally occurring retinoid derivative with diverse biological effects. 4-Hydroxyretinoic acid is formed from retinol catalyzed by cytochrome P-450 isozyme(s), and is mainly metabolized by the liver in the body. 4-Hydroxyretinoic acid also serves as the substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2B7. 4-Hydroxyretinoic acid regulates gene expression and cell differentiation via binding to nuclear receptor RAR (Retinoic Acid Receptor), and activates RARs and RXR-alpha, to induce cancer cell apoptosis. In addition, 4-Hydroxyretinoic acid is also involved in various physiological processes such as immune regulation, neuroprotection, and anti-oxidation.
More description
|
|
| DC66070 | WAY-620472 Featured |
altering the lifespan of a eukaryotic organism; PPAR modulator;
More description
|
|
| DC66069 | DAPK-IN-2 Featured |
DAPK-IN-2 is a DAPK inhibitor. DAPK-IN-2 can be used for the research of cerebral infarction and ischemic diseases.
More description
|
|
| DC71390 | Ribavirin carboxylic acid Featured |
Ribavirin carboxylic acid (TR-COOH) is a metabolite of ribavirin, ribavirin has strong antiviral activity.
More description
|
|
| DC66068 | WAY-326275 Featured |
inhibitor of lethal toxin pathway; useful for modulating hepatocyte growth factor/scatter factor activity;
More description
|
|